Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease

Yanhui Xu, Andrew S. Flies, Dallas B. Flies, Gefeng Zhu, Sudarshan Anand, Sarah J. Flies, Haiying Xu, Robert A. Anders, Wayne W. Hancock, Lieping Chen, Koji Tamada

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Decoy lymphotoxin β receptor (LTβR) has potent immune inhibitory activities and thus represents a promising biologic for the treatment of inflammation, autoimmune diseases, and graft-versus-host disease (GVHD). As this reagent interrupts multiple molecular interactions, including LTβ-LTβR and LIGHT-HVEM/LTβR, underlying molecular mechanisms have yet to be fully understood. In this study, we demonstrate that blockade of the LIGHT-HVEM pathway is sufficient to induce amelioration of GVHD in mouse models. Anti-host cytotoxic T lymphocyte (CTL) activity following in vivo transfer of allogeneic lymphocytes was completely abrogated when LIGHT- or HVEM-deficient (KO) T cells were used as donor cells. Accordingly, survival of the recipient mice following the transfer of allogeneic bone marrow cells plus LIGHT-KO or HVEM-KO T cells was significantly prolonged. In the absence of LIGHT-HVEM costimulation, alloreactive donor T cells undergo vigorous apoptosis while their proliferative potential remains intact. Furthermore, we prepared a neutralizing monoclonal antibody (mAb) specific to HVEM and showed that administration of anti-HVEM mAb profoundly ameliorated GVHD and led to complete hematopoietic chimerism with donor cells. Collectively, our results demonstrate an indispensable role of LIGHT-HVEM costimulation in the pathogenesis of GVHD and illustrate a novel target for selective immunotherapy in allogeneic bone marrow transplantation.

Original languageEnglish (US)
Pages (from-to)4097-4104
Number of pages8
JournalBlood
Volume109
Issue number9
DOIs
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

Graft vs Host Disease
Grafts
T-cells
Light
Lymphotoxin-alpha
T-Lymphocytes
Bone
Therapeutics
Monoclonal Antibodies
Chimerism
Lymphocytes
Molecular interactions
Homologous Transplantation
Cytotoxic T-Lymphocytes
Neutralizing Antibodies
Bone Marrow Transplantation
Bone Marrow Cells
Immunotherapy
Autoimmune Diseases
Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. / Xu, Yanhui; Flies, Andrew S.; Flies, Dallas B.; Zhu, Gefeng; Anand, Sudarshan; Flies, Sarah J.; Xu, Haiying; Anders, Robert A.; Hancock, Wayne W.; Chen, Lieping; Tamada, Koji.

In: Blood, Vol. 109, No. 9, 01.05.2007, p. 4097-4104.

Research output: Contribution to journalArticle

Xu, Y, Flies, AS, Flies, DB, Zhu, G, Anand, S, Flies, SJ, Xu, H, Anders, RA, Hancock, WW, Chen, L & Tamada, K 2007, 'Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease', Blood, vol. 109, no. 9, pp. 4097-4104. https://doi.org/10.1182/blood-2006-09-047332
Xu, Yanhui ; Flies, Andrew S. ; Flies, Dallas B. ; Zhu, Gefeng ; Anand, Sudarshan ; Flies, Sarah J. ; Xu, Haiying ; Anders, Robert A. ; Hancock, Wayne W. ; Chen, Lieping ; Tamada, Koji. / Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. In: Blood. 2007 ; Vol. 109, No. 9. pp. 4097-4104.
@article{e426d2fd3c98459ba5ac6011a30e62e4,
title = "Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease",
abstract = "Decoy lymphotoxin β receptor (LTβR) has potent immune inhibitory activities and thus represents a promising biologic for the treatment of inflammation, autoimmune diseases, and graft-versus-host disease (GVHD). As this reagent interrupts multiple molecular interactions, including LTβ-LTβR and LIGHT-HVEM/LTβR, underlying molecular mechanisms have yet to be fully understood. In this study, we demonstrate that blockade of the LIGHT-HVEM pathway is sufficient to induce amelioration of GVHD in mouse models. Anti-host cytotoxic T lymphocyte (CTL) activity following in vivo transfer of allogeneic lymphocytes was completely abrogated when LIGHT- or HVEM-deficient (KO) T cells were used as donor cells. Accordingly, survival of the recipient mice following the transfer of allogeneic bone marrow cells plus LIGHT-KO or HVEM-KO T cells was significantly prolonged. In the absence of LIGHT-HVEM costimulation, alloreactive donor T cells undergo vigorous apoptosis while their proliferative potential remains intact. Furthermore, we prepared a neutralizing monoclonal antibody (mAb) specific to HVEM and showed that administration of anti-HVEM mAb profoundly ameliorated GVHD and led to complete hematopoietic chimerism with donor cells. Collectively, our results demonstrate an indispensable role of LIGHT-HVEM costimulation in the pathogenesis of GVHD and illustrate a novel target for selective immunotherapy in allogeneic bone marrow transplantation.",
author = "Yanhui Xu and Flies, {Andrew S.} and Flies, {Dallas B.} and Gefeng Zhu and Sudarshan Anand and Flies, {Sarah J.} and Haiying Xu and Anders, {Robert A.} and Hancock, {Wayne W.} and Lieping Chen and Koji Tamada",
year = "2007",
month = "5",
day = "1",
doi = "10.1182/blood-2006-09-047332",
language = "English (US)",
volume = "109",
pages = "4097--4104",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease

AU - Xu, Yanhui

AU - Flies, Andrew S.

AU - Flies, Dallas B.

AU - Zhu, Gefeng

AU - Anand, Sudarshan

AU - Flies, Sarah J.

AU - Xu, Haiying

AU - Anders, Robert A.

AU - Hancock, Wayne W.

AU - Chen, Lieping

AU - Tamada, Koji

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Decoy lymphotoxin β receptor (LTβR) has potent immune inhibitory activities and thus represents a promising biologic for the treatment of inflammation, autoimmune diseases, and graft-versus-host disease (GVHD). As this reagent interrupts multiple molecular interactions, including LTβ-LTβR and LIGHT-HVEM/LTβR, underlying molecular mechanisms have yet to be fully understood. In this study, we demonstrate that blockade of the LIGHT-HVEM pathway is sufficient to induce amelioration of GVHD in mouse models. Anti-host cytotoxic T lymphocyte (CTL) activity following in vivo transfer of allogeneic lymphocytes was completely abrogated when LIGHT- or HVEM-deficient (KO) T cells were used as donor cells. Accordingly, survival of the recipient mice following the transfer of allogeneic bone marrow cells plus LIGHT-KO or HVEM-KO T cells was significantly prolonged. In the absence of LIGHT-HVEM costimulation, alloreactive donor T cells undergo vigorous apoptosis while their proliferative potential remains intact. Furthermore, we prepared a neutralizing monoclonal antibody (mAb) specific to HVEM and showed that administration of anti-HVEM mAb profoundly ameliorated GVHD and led to complete hematopoietic chimerism with donor cells. Collectively, our results demonstrate an indispensable role of LIGHT-HVEM costimulation in the pathogenesis of GVHD and illustrate a novel target for selective immunotherapy in allogeneic bone marrow transplantation.

AB - Decoy lymphotoxin β receptor (LTβR) has potent immune inhibitory activities and thus represents a promising biologic for the treatment of inflammation, autoimmune diseases, and graft-versus-host disease (GVHD). As this reagent interrupts multiple molecular interactions, including LTβ-LTβR and LIGHT-HVEM/LTβR, underlying molecular mechanisms have yet to be fully understood. In this study, we demonstrate that blockade of the LIGHT-HVEM pathway is sufficient to induce amelioration of GVHD in mouse models. Anti-host cytotoxic T lymphocyte (CTL) activity following in vivo transfer of allogeneic lymphocytes was completely abrogated when LIGHT- or HVEM-deficient (KO) T cells were used as donor cells. Accordingly, survival of the recipient mice following the transfer of allogeneic bone marrow cells plus LIGHT-KO or HVEM-KO T cells was significantly prolonged. In the absence of LIGHT-HVEM costimulation, alloreactive donor T cells undergo vigorous apoptosis while their proliferative potential remains intact. Furthermore, we prepared a neutralizing monoclonal antibody (mAb) specific to HVEM and showed that administration of anti-HVEM mAb profoundly ameliorated GVHD and led to complete hematopoietic chimerism with donor cells. Collectively, our results demonstrate an indispensable role of LIGHT-HVEM costimulation in the pathogenesis of GVHD and illustrate a novel target for selective immunotherapy in allogeneic bone marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=34247356558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247356558&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-09-047332

DO - 10.1182/blood-2006-09-047332

M3 - Article

C2 - 17179227

AN - SCOPUS:34247356558

VL - 109

SP - 4097

EP - 4104

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -